Discussion Points Include:

• Explore strategies for prioritizing which biophysical assays to deploy first across diverse target classes
• Discuss how to balance high-throughput screens with deeper mechanistic assays to build confidence in early hits
• Examine how to define “confidence” in binding and progression decisions for challenging modalities, including fragments, PROTACs, intrinsically disordered proteins, and RNA-binding targets
• Share insights into managing conflicting or ambiguous data and deciding which hits to advance